ClinicalTrials.gg
CompletedNCT04737187SUNLIGHTUpdated Sep 24, 2024Results posted

Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients

A Phase 3 interventional study of Trifluridine/Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer, sponsored by Taiho Oncology, Inc.. Completed at 99 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-24.

Sponsored by Taiho Oncology, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
492
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 230 studies testing bevacizumab in Colorectal Neoplasms — 49 open to participants now, 61 under way, 11 of them phase 3. Bevacizumab · Colorectal Neoplasms.

Enrollment
23rd of 224
492 · median 63
Started
2020
with 9 others
Phase 3
42 of 230
4 open now
Registered
177th of 230
by date

Among the 230 studies testing bevacizumab in Colorectal Neoplasms, this one is the 23rd largest by enrollment of the 224 interventional ones that give a count, is one of 10 that started in 2020, is one of 42 in phase 3, and was the 177th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

49 of the 230 studies testing bevacizumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

44 more — sign in →

By country, each count listing its studies:

All 49 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies testing bevacizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This study is designed as an international, open-label, controlled two-arm, randomized phase III comparison study evaluating the efficacy and safety of trifluridine/tipiracil in combination with bevacizumab versus trifluridine/tipiracil monotherapy in patients with refractory mCRC.

Read the detailed description

This is an international, open-label, controlled two-arm, randomised phase III study evaluating the efficacy and safety of trifluridine/tipiracil in combination with bevacizumab versus trifluridine/tipiracil monotherapy in patients with refractory mCRC. The analysis will be done after 331 events are reported. In order to observe this number of events, 490 patients will be randomised (1:1) to receive trifluridine/tipiracil in combination with bevacizumab (experimental arm) or trifluridine/tipiracil monotherapy (control arm).

03

Conditions studied

  • Refractory Metastatic Colorectal Cancer

Keywords

  • trifluridine/tipiracil/lonsurf
  • TAS102
  • bevacizumab
  • avastin
  • RAS status (wild type, mutant)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has confirmed unresectable adenocarcinoma of the colon or rectum (all other histological types are excluded).
  2. RAS status must have been previously determined (mutant or wild-type) based on local assessment of tumor .
  3. Has received a maximum of 2 prior chemotherapy regimens for the treatment of advanced colorectal cancer and had demonstrated progressive disease or intolerance to their last regimen.
  4. Has measurable or non- as defined by version 1.1
  5. Is able to swallow oral tablets.
  6. Estimated ≥12 weeks.
  7. performance status (ECOG PS) 0 or 1

Exclusion criteria

Exclusion Criteria:

  1. More than 2 prior chemotherapy regimens for the treatment of advanced colorectal cancer.
  2. Pregnancy, lactating female or possibility of becoming pregnant during the study.
  3. Patients currently receiving or having received anticancer therapies within 4 weeks prior to randomization.
  4. Has not recovered from non-hematologic grade ≥ 3 toxicity of previous anticancer therapy prior to randomization (excluding alopecia, and skin pigmentation).
  5. Has symptomatic central nervous system that are neurologically unstable or requiring increasing doses of to control CNS disease.
  6. Has severe or uncontrolled active acute or chronic infection.
  7. Has active or history of interstitial lung disease and/or pneumonitis, or pulmonary hypertension.
  8. Known or Virus infection.
  9. Known carriers of antibodies.
  10. Confirmed uncontrolled arterial hypertension (defined as systolic blood pressure ≥ 150 mm Hg and/or diastolic blood pressure ≥ 100 mm Hg) or uncontrolled or symptomatic arrhythmia.
  11. Deep arterial thromboembolic events including cerebrovascular accident or myocardial infarction within the last 6 months prior to randomization.
  12. Treatment with any of the following within the specified time frame prior to randomization:

    • major surgery within 4 weeks prior to randomisation (the surgical incision should be fully healed prior to study drug administration), or has not recovered from side effects of previous surgery, or patient that may require major surgery during the study
    • Prior radiotherapy if completed less than 4 weeks before randomisation, except if provided as a short course for symptoms palliation only.
    • Drainage for ascites, pleural effusion or pericardial fluid within 4 weeks prior to randomization
  13. Other clinically significant medical conditions.
  14. Other .
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
492 participants (actual)

Study arms

  • Experimental
    Trifluridine/Tipiracil + Bevacizumab

    Participants were administered 35 milligrams per square meter per dose (mg/m²/dose) trifluridine/tipiracil (FTD/TPI) orally twice a day (BID), within 1 hour after completion of morning and evening meals, 5 days on (Day 1 to 5 and Day 8 to 12) with 2 days off (Day 6 to 7 an Day 13 to 14), over 2 weeks, followed by a 14-day rest; with bevacizumab (5 milligrams per kilogram \[mg/kg\], intravenous \[IV\] infusion administered every 2 weeks (Day 1 and Day 15). This treatment cycle was repeated every 4 weeks.

    Drug: Trifluridine/Tipiracil · Drug: Bevacizumab

  • Active comparator
    Trifluridine/Tipiracil

    Participants were administered 35 mg/m²/dose of FTD/TPI orally BID, within 1 hour after completion of morning and evening meals, 5 days on (Day 1 to 5 and Day 8 to 12) with 2 days off (Day 6 to 7 and Day 13 to 14), over 2 weeks, followed by a 14-day rest. This treatment cycle was repeated every 4 weeks.

    Drug: Trifluridine/Tipiracil

Interventions

  • DrugTrifluridine/Tipiracil

    Taken by mouth two times a day, 5 days on/2 days off, over 2 weeks, followed by a 14-day rest

    Also known as: TAS102, S 95005, Lonsurf

  • administered every 2 weeks (Day 1 and Day 15)

    Also known as: Avastin

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall survival defined as the observed time elapsed between the date of randomization and the date of death due to any cause. The primary estimand of interest was defined to assess the effect of the randomized treatments on the survival duration in all participants regardless of whether or not intercurrent events had occurred (treatment policy strategy). Analysis was performed using Kaplan- Meier method.

    Time frame: From date of randomization to the death due to any cause or cut-off date, whichever comes first (maximum duration: up to 20 months)

  2. Survival Probability at 6 Months

    Overall survival defined as the observed time elapsed between the date of randomization and the date of death due to any cause. The primary estimand of interest was defined to assess the effect of the randomized treatments on the survival duration in all participants regardless of whether or not intercurrent events had occurred (treatment policy strategy). Analysis was performed using Kaplan- Meier method. In this outcome measure, data of survival probability at 6 months was reported.

    Time frame: From date of randomization until 6 months post treatment

  3. Survival Probability at 12 Months

    Overall survival defined as the observed time elapsed between the date of randomization and the date of death due to any cause. The primary estimand of interest was defined to assess the effect of the randomized treatments on the survival duration in all participants regardless of whether or not intercurrent events had occurred (treatment policy strategy). Analysis was performed using Kaplan- Meier method. In this outcome measure, data of survival probability at 12 months was reported.

    Time frame: From date of randomization until 12 months post treatment

  4. Survival Probability at 18 Months

    Overall survival defined as the observed time elapsed between the date of randomization and the date of death due to any cause. The primary estimand of interest was defined to assess the effect of the randomized treatments on the survival duration in all participants regardless of whether or not intercurrent events had occurred (treatment policy strategy). Analysis was performed using Kaplan- Meier method. In this outcome measure, data of survival probability at 18 months was reported.

    Time frame: From date of randomization until 18 months post treatment

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the time elapsed between the date of randomisation and the date of radiological tumour progression as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) assessed by investigator, or death (from any cause), whichever comes first. Progressive Disease (PD) as per RECIST 1.1: at least a 20 percent (%) increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Analysis was performed by Kaplan-Meier method.

    Time frame: From randomization to the date of radiological tumour progression or death due to any cause or data cut-off date whichever comes first (i.e., up to 20 months)

  2. Probability of Participants With Progression Free Survival at 3, 6, 9 and 12 Months

    PFS was defined as the time elapsed between the date of randomisation and the date of radiological tumour progression as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) assessed by investigator, or death (from any cause), whichever comes first. Progressive Disease (PD) as per RECIST 1.1: at least a 20 percent (%) increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Analysis was performed by Kaplan-Meier method. In this outcome measure, data of PFS at 3 months was reported.

    Time frame: From randomization until 3, 6, 9, and 12 months post treatment

  3. Overall Response Rate (ORR)

    Objective response was defined as percentage of participants who achieved complete response (CR) or partial response (PR) according to the RECIST version 1.1 and using investigator's tumour assessment. As per RECIST 1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters.

    Time frame: From the date of randomization to the date of documentation of progression or death due to any cause or data cut-off, whichever occurred first (i.e., up to 20 months)

  4. Percentage of Participants With Disease Control

    Disease control is defined as percentage of participants who achieved CR or PR, or stable disease (SD) as per RECIST 1.1 and using investigator's tumour assessment from the date of randomization to until disease progression or death due to any cause. As per RECIST 1.1, CR: disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters. PD: at least 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions.

    Time frame: From randomization to the date of first documented tumor progression, death due to any cause or data cut-off date whichever comes first (i.e., up to 20 months)

  5. Number of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAEs)

    An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (time from the first dose of study treatment up to 30 days after the last dose of study treatment). TEAEs included both SAEs and non-SAEs.

    Time frame: From baseline (Cycle 1 Day 1) up to 30 days after the last dose of study drug (i.e., up to 30.7 months)

  6. European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30): Time to Definitive Deterioration of >=10 Points in Sub-scale Scores - Kaplan-Meier Analysis

    EORTC QLQ-C30: 30 item questionnaires with 5 multi-item functional subscales (physical, role, cognitive, emotional, social functioning), 3 multi-item symptom scales (fatigue, nausea/vomiting, and pain), global health/quality of life (QOL) subscale and 6 single items assessing other cancer related symptoms (dyspnea, sleep disturbance, appetite, diarrhea, constipation and financial impact of cancer). It employed twenty-eight 4-point Likert scales with responses from "not at all" to "very much" and GHS/QoL, scored on scale of 1 (very poor) to 7 (excellent). All scales are transformed from raw scores to linear scales ranging 0 to 100. Higher score for functional \& GHS/QoL = higher level of functioning, \& higher score for symptoms scales = higher symptom burden. Time to definitive \>=10 points deterioration: time from date of randomization to first deterioration in QoL score \>=10 points compared to baseline with no later improvement or death due to any cause. Kaplan-Meier method was used.

    Time frame: Date of randomization to first deterioration in QoL score >=10 points or death due to any cause, which ever occurred first (i.e., up to 20 months)

  7. European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30): Time to Definitive Deterioration of >=10 Points in the Global Health Status Score - Kaplan-Meier Analysis

    EORTC QLQ-C30: 30 item questionnaires composed of 5 multi-item functional subscales (physical, role, cognitive, emotional, social functioning), 3 multi-item symptom scales (fatigue, nausea/vomiting, and pain), global health/QOL subscale and 6 single items assessing other cancer related symptoms (dyspnea, sleep disturbance, appetite, diarrhea, constipation and financial impact of cancer). It employed twenty-eight 4-point Likert scales with responses from "not at all" to "very much" and GHS/QoL, scored on scale of 1 (very poor) to 7 (excellent). All scales are transformed from raw scores to linear scales ranging 0 to 100. Higher score for functional \& GHS/QoL = higher level of functioning, \& higher score for symptoms scales = higher symptom burden. Time to definitive \>=10 points deterioration: time from date of randomization to the first deterioration in QoL score \>=10 points compared to baseline with no later improvement or death due to any cause. Kaplan-Meier method was used.

    Time frame: Date of randomization to first deterioration in QoL score >=10 points or death due to any cause, which ever occurred first (i.e., up to 20 months)

  8. Change From Baseline in European Quality of Life Group Questionnaire With 5 Dimensions and 5 Levels Per Dimension (EQ-5D-5L): Health State Utility Index Value at Specified Timepoints

    The EQ-5D-5L is a standardized measure of health status that provides a general assessment of health utility and consist in 2 sections a descriptive system comprising 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and Visual Analog Scale (VAS). Each dimension has a 5-level response: no problems, slight problems, moderate problems, severe problems, and extreme problems. Response options are measured with a 5-point Likert scale. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state and lower score indicate worse health state.

    Time frame: Baseline, Cycle 1, Cycle 2, Cycle 3, Cycle 4, Cycle 5, Cycle 6, Cycle 7, Cycle 8, Cycle 9, Cycle 10, Cycle 11, Cycle 12, Cycle 13 and Cycle 14

  9. Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Score: Visual Analogic Scale (VAS) at Specified Timepoints

    The EQ-5D-5L is a standardized measure of health status that provides a general assessment of health utility and consist of 2 sections; descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and a VAS. The VAS records the respondent's self-rated health on a 20 centimeter (cm) vertical VAS; the scale went from 0 (worst imaginable health state) to 100 (best imaginable health state). This information can be used as a quantitative measure of health as judged by the individual respondents.

    Time frame: Baseline, Cycle 1, Cycle 2, Cycle 3, Cycle 4, Cycle 5, Cycle 6, Cycle 7, Cycle 8, Cycle 9, Cycle 10, Cycle 11, Cycle 12, Cycle 13 and Cycle 14

07

Results

Posted Dec 26, 2023

Participant flow

The study was conducted at 99 active sites in 13 countries. A total of 659 participants were screened, of which 492 participants were randomized and treated.

Participant flow — Overall Study
MilestoneTrifluridine/Tipiracil + BevacizumabTrifluridine/Tipiracil
Started246246
Completed00
Not completed246246
Withdrew: Switched to marketed drug324
Withdrew: Radiological progressive disease145146
Withdrew: Clinical progressive disease2020
Withdrew: Radiological and clinical progressive disease2652
Withdrew: Adverse event1616
Withdrew: Physician decision20
Withdrew: Withdrawal by subject58

Outcome measures

PrimaryOverall Survival (OS)

Overall survival defined as the observed time elapsed between the date of randomization and the date of death due to any cause. The primary estimand of interest was defined to assess the effect of the randomized treatments on the survival duration in all participants regardless of whether or not intercurrent events had occurred (treatment policy strategy). Analysis was performed using Kaplan- Meier method.

Time frame:
From date of randomization to the death due to any cause or cut-off date, whichever comes first (maximum duration: up to 20 months)
Reported as:
Median · months
Overall Survival (OS)
monthsTrifluridine/Tipiracil + BevacizumabTrifluridine/Tipiracil
Overall Survival (OS)10.78 (9.36 to 11.83)7.46 (6.34 to 8.57)
Statistical analysis
  • Trifluridine/Tipiracil + Bevacizumab vs Trifluridine/Tipiracil · Stratified log-rank test · p = < 0.001 (Stratified log-rank test, with a target p-value \< 0.025 for level of significance.) · Hazard ratio (hr): 0.61 · 95% CI 0.49 to 0.77Hazard ratio and 95% confidence interval was estimated with stratified Cox proportional hazard model.
PrimarySurvival Probability at 6 Months

Overall survival defined as the observed time elapsed between the date of randomization and the date of death due to any cause. The primary estimand of interest was defined to assess the effect of the randomized treatments on the survival duration in all participants regardless of whether or not intercurrent events had occurred (treatment policy strategy). Analysis was performed using Kaplan- Meier method. In this outcome measure, data of survival probability at 6 months was reported.

Time frame:
From date of randomization until 6 months post treatment
Reported as:
Number · probability of participants
Survival Probability at 6 Months
probability of participantsTrifluridine/Tipiracil + BevacizumabTrifluridine/Tipiracil
Survival Probability at 6 Months0.77 (0.72 to 0.82)0.61 (0.55 to 0.67)
PrimarySurvival Probability at 12 Months

Overall survival defined as the observed time elapsed between the date of randomization and the date of death due to any cause. The primary estimand of interest was defined to assess the effect of the randomized treatments on the survival duration in all participants regardless of whether or not intercurrent events had occurred (treatment policy strategy). Analysis was performed using Kaplan- Meier method. In this outcome measure, data of survival probability at 12 months was reported.

Time frame:
From date of randomization until 12 months post treatment
Reported as:
Number · probability of participants
Survival Probability at 12 Months
probability of participantsTrifluridine/Tipiracil + BevacizumabTrifluridine/Tipiracil
Survival Probability at 12 Months0.43 (0.36 to 0.49)0.30 (0.24 to 0.36)
PrimarySurvival Probability at 18 Months

Overall survival defined as the observed time elapsed between the date of randomization and the date of death due to any cause. The primary estimand of interest was defined to assess the effect of the randomized treatments on the survival duration in all participants regardless of whether or not intercurrent events had occurred (treatment policy strategy). Analysis was performed using Kaplan- Meier method. In this outcome measure, data of survival probability at 18 months was reported.

Time frame:
From date of randomization until 18 months post treatment
Reported as:
Number · probability of participants
Survival Probability at 18 Months
probability of participantsTrifluridine/Tipiracil + BevacizumabTrifluridine/Tipiracil
Survival Probability at 18 Months0.28 (0.19 to 0.37)0.15 (0.09 to 0.22)
SecondaryProgression Free Survival (PFS)

PFS was defined as the time elapsed between the date of randomisation and the date of radiological tumour progression as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) assessed by investigator, or death (from any cause), whichever comes first. Progressive Disease (PD) as per RECIST 1.1: at least a 20 percent (%) increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Analysis was performed by Kaplan-Meier method.

Time frame:
From randomization to the date of radiological tumour progression or death due to any cause or data cut-off date whichever comes first (i.e., up to 20 months)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsTrifluridine/Tipiracil + BevacizumabTrifluridine/Tipiracil
Progression Free Survival (PFS)5.55 (4.50 to 5.88)2.40 (2.07 to 3.22)
Statistical analysis
  • Trifluridine/Tipiracil + Bevacizumab vs Trifluridine/Tipiracil · Stratified log-rank test · p = < 0.001 (Stratified log-rank test, with a target p-value \< 0.025 for level of significance.) · Hazard ratio (hr): 0.44 · 95% CI 0.36 to 0.54Hazard ratio and 95% confidence interval was estimated with stratified Cox proportional hazard model.
SecondaryProbability of Participants With Progression Free Survival at 3, 6, 9 and 12 Months

PFS was defined as the time elapsed between the date of randomisation and the date of radiological tumour progression as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) assessed by investigator, or death (from any cause), whichever comes first. Progressive Disease (PD) as per RECIST 1.1: at least a 20 percent (%) increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Analysis was performed by Kaplan-Meier method. In this outcome measure, data of PFS at 3 months was reported.

Time frame:
From randomization until 3, 6, 9, and 12 months post treatment
Reported as:
Number · probability of participants
Probability of Participants With Progression Free Survival at 3, 6, 9 and 12 Months
probability of participantsTrifluridine/Tipiracil + BevacizumabTrifluridine/Tipiracil
At 3 Months0.73 (0.67 to 0.78)0.45 (0.39 to 0.51)
At 6 Months0.43 (0.37 to 0.49)0.16 (0.11 to 0.21)
At 9 Months0.28 (0.22 to 0.34)0.05 (0.03 to 0.09)
At 12 Months0.16 (0.12 to 0.21)0.01 (0.00 to 0.03)
SecondaryOverall Response Rate (ORR)

Objective response was defined as percentage of participants who achieved complete response (CR) or partial response (PR) according to the RECIST version 1.1 and using investigator's tumour assessment. As per RECIST 1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters.

Time frame:
From the date of randomization to the date of documentation of progression or death due to any cause or data cut-off, whichever occurred first (i.e., up to 20 months)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsTrifluridine/Tipiracil + BevacizumabTrifluridine/Tipiracil
Overall Response Rate (ORR)6.10 (3.45 to 9.86)1.22 (0.25 to 3.52)
SecondaryPercentage of Participants With Disease Control

Disease control is defined as percentage of participants who achieved CR or PR, or stable disease (SD) as per RECIST 1.1 and using investigator's tumour assessment from the date of randomization to until disease progression or death due to any cause. As per RECIST 1.1, CR: disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters. PD: at least 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions.

Time frame:
From randomization to the date of first documented tumor progression, death due to any cause or data cut-off date whichever comes first (i.e., up to 20 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Control
percentage of participantsTrifluridine/Tipiracil + BevacizumabTrifluridine/Tipiracil
Percentage of Participants With Disease Control69.51 (63.35 to 75.2)41.87 (35.63 to 48.31)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAEs)

An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (time from the first dose of study treatment up to 30 days after the last dose of study treatment). TEAEs included both SAEs and non-SAEs.

Time frame:
From baseline (Cycle 1 Day 1) up to 30 days after the last dose of study drug (i.e., up to 30.7 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAE) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsTrifluridine/Tipiracil + BevacizumabTrifluridine/Tipiracil
TEAE241241
TESAE6679
SecondaryEuropean Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30): Time to Definitive Deterioration of >=10 Points in Sub-scale Scores - Kaplan-Meier Analysis

EORTC QLQ-C30: 30 item questionnaires with 5 multi-item functional subscales (physical, role, cognitive, emotional, social functioning), 3 multi-item symptom scales (fatigue, nausea/vomiting, and pain), global health/quality of life (QOL) subscale and 6 single items assessing other cancer related symptoms (dyspnea, sleep disturbance, appetite, diarrhea, constipation and financial impact of cancer). It employed twenty-eight 4-point Likert scales with responses from "not at all" to "very much" and GHS/QoL, scored on scale of 1 (very poor) to 7 (excellent). All scales are transformed from raw scores to linear scales ranging 0 to 100. Higher score for functional \& GHS/QoL = higher level of functioning, \& higher score for symptoms scales = higher symptom burden. Time to definitive \>=10 points deterioration: time from date of randomization to first deterioration in QoL score \>=10 points compared to baseline with no later improvement or death due to any cause. Kaplan-Meier method was used.

Time frame:
Date of randomization to first deterioration in QoL score >=10 points or death due to any cause, which ever occurred first (i.e., up to 20 months)
Reported as:
Median · months
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30): Time to Definitive Deterioration of >=10 Points in Sub-scale Scores - Kaplan-Meier Analysis
monthsTrifluridine/Tipiracil + BevacizumabTrifluridine/Tipiracil
Physical functioning8.97 (8.15 to 11.83)4.50 (3.71 to 5.62)
Role functioning8.57 (7.49 to 10.94)4.40 (3.78 to 5.06)
Emotional functioning9.95 (8.51 to 12.12)5.85 (4.70 to 6.60)
Cognitive functioning9.36 (8.34 to 12.25)4.73 (4.07 to 6.11)
Social functioning8.97 (7.85 to 11.86)4.93 (4.14 to 5.88)
Fatigue8.21 (6.11 to 9.95)4.04 (3.19 to 4.83)
Nausea and vomiting9.36 (8.51 to 11.86)5.06 (4.27 to 6.31)
Pain8.57 (6.96 to 10.41)4.34 (3.29 to 5.16)
Dyspnoea9.36 (8.54 to 12.25)5.65 (4.40 to 6.60)
Insomnia9.36 (8.54 to 12.25)5.75 (4.70 to 6.80)
Appetite loss8.34 (6.70 to 10.94)4.66 (3.94 to 6.04)
Constipation9.46 (8.34 to 12.12)5.55 (4.63 to 6.67)
Diarrhoea10.41 (8.84 to 14.49)5.52 (4.70 to 6.60)
Financial difficulties9.36 (8.34 to 12.12)6.11 (5.06 to 6.93)
SecondaryEuropean Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30): Time to Definitive Deterioration of >=10 Points in the Global Health Status Score - Kaplan-Meier Analysis

EORTC QLQ-C30: 30 item questionnaires composed of 5 multi-item functional subscales (physical, role, cognitive, emotional, social functioning), 3 multi-item symptom scales (fatigue, nausea/vomiting, and pain), global health/QOL subscale and 6 single items assessing other cancer related symptoms (dyspnea, sleep disturbance, appetite, diarrhea, constipation and financial impact of cancer). It employed twenty-eight 4-point Likert scales with responses from "not at all" to "very much" and GHS/QoL, scored on scale of 1 (very poor) to 7 (excellent). All scales are transformed from raw scores to linear scales ranging 0 to 100. Higher score for functional \& GHS/QoL = higher level of functioning, \& higher score for symptoms scales = higher symptom burden. Time to definitive \>=10 points deterioration: time from date of randomization to the first deterioration in QoL score \>=10 points compared to baseline with no later improvement or death due to any cause. Kaplan-Meier method was used.

Time frame:
Date of randomization to first deterioration in QoL score >=10 points or death due to any cause, which ever occurred first (i.e., up to 20 months)
Reported as:
Median · months
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30): Time to Definitive Deterioration of >=10 Points in the Global Health Status Score - Kaplan-Meier Analysis
monthsTrifluridine/Tipiracil + BevacizumabTrifluridine/Tipiracil
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30): Time to Definitive Deterioration of >=10 Points in the Global Health Status Score - Kaplan-Meier Analysis8.54 (7.49 to 10.94)4.70 (4.01 to 5.78)
SecondaryChange From Baseline in European Quality of Life Group Questionnaire With 5 Dimensions and 5 Levels Per Dimension (EQ-5D-5L): Health State Utility Index Value at Specified Timepoints

The EQ-5D-5L is a standardized measure of health status that provides a general assessment of health utility and consist in 2 sections a descriptive system comprising 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and Visual Analog Scale (VAS). Each dimension has a 5-level response: no problems, slight problems, moderate problems, severe problems, and extreme problems. Response options are measured with a 5-point Likert scale. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state and lower score indicate worse health state.

Time frame:
Baseline, Cycle 1, Cycle 2, Cycle 3, Cycle 4, Cycle 5, Cycle 6, Cycle 7, Cycle 8, Cycle 9, Cycle 10, Cycle 11, Cycle 12, Cycle 13 and Cycle 14
Reported as:
Mean · score on a scale
Change From Baseline in European Quality of Life Group Questionnaire With 5 Dimensions and 5 Levels Per Dimension (EQ-5D-5L): Health State Utility Index Value at Specified Timepoints
score on a scaleTrifluridine/Tipiracil + BevacizumabTrifluridine/Tipiracil
Cycle 10.004 ± 0.1250.001 ± 0.163
Cycle 2-0.003 ± 0.114-0.030 ± 0.153
Cycle 3-0.014 ± 0.1070.002 ± 0.188
Cycle 4-0.016 ± 0.111-0.014 ± 0.209
Cycle 5-0.003 ± 0.1010.004 ± 0.120
Cycle 6-0.010 ± 0.112-0.003 ± 0.094
Cycle 7-0.007 ± 0.0780.002 ± 0.105
Cycle 8-0.016 ± 0.097-0.028 ± 0.109
Cycle 9-0.024 ± 0.1490.032 ± 0.085
Cycle 10-0.003 ± 0.0940.018 ± 0.106
Cycle 11-0.008 ± 0.1050.008 ± 0.104
Cycle 12-0.025 ± 0.1130.030 ± 0.039
Cycle 13-0.037 ± 0.1120.015
Cycle 14-0.034 ± 0.0620.016
SecondaryChange From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Score: Visual Analogic Scale (VAS) at Specified Timepoints

The EQ-5D-5L is a standardized measure of health status that provides a general assessment of health utility and consist of 2 sections; descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and a VAS. The VAS records the respondent's self-rated health on a 20 centimeter (cm) vertical VAS; the scale went from 0 (worst imaginable health state) to 100 (best imaginable health state). This information can be used as a quantitative measure of health as judged by the individual respondents.

Time frame:
Baseline, Cycle 1, Cycle 2, Cycle 3, Cycle 4, Cycle 5, Cycle 6, Cycle 7, Cycle 8, Cycle 9, Cycle 10, Cycle 11, Cycle 12, Cycle 13 and Cycle 14
Reported as:
Mean · score on a scale
Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions, 5 Levels (EQ-5D-5L) Score: Visual Analogic Scale (VAS) at Specified Timepoints
score on a scaleTrifluridine/Tipiracil + BevacizumabTrifluridine/Tipiracil
Cycle 12.095 ± 16.2560.058 ± 15.749
Cycle 20.852 ± 15.696-4.242 ± 18.302
Cycle 30.297 ± 17.618-1.604 ± 15.729
Cycle 4-0.521 ± 18.177-3.247 ± 17.769
Cycle 51.904 ± 16.908-1.271 ± 16.738
Cycle 62.786 ± 16.162-3.513 ± 18.602
Cycle 71.500 ± 16.730-2.708 ± 16.573
Cycle 80.221 ± 15.635-0.353 ± 16.328
Cycle 9-1.745 ± 14.0853.400 ± 11.928
Cycle 10-1.953 ± 13.991-4.500 ± 25.785
Cycle 11-1.212 ± 16.3282.833 ± 16.388
Cycle 122.385 ± 13.6748.000 ± 15.188
Cycle 13-2.056 ± 15.75713.000
Cycle 140.545 ± 15.95213.000

Adverse events

Collected over Serious AEs and Other AEs: From baseline (Cycle 1 Day 1) up to 30 days after the last dose of study drug (i.e., up to 30.7 months); All-cause mortality: from baseline (Cycle 1 Day 1) up to end of the study (i.e., up to 33.6 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trifluridine/Tipiracil + Bevacizumab208/246 (84.6%)66/246 (26.8%)241/246 (98%)
Trifluridine/Tipiracil224/246 (91.1%)79/246 (32.1%)241/246 (98%)
Most frequent serious events
Showing 10 of 136
Most frequent serious events
EventTrifluridine/Tipiracil + BevacizumabTrifluridine/Tipiracil
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/24611/246
AnaemiaBlood and lymphatic system disorders3/2469/246
Intestinal obstructionGastrointestinal disorders9/2465/246
Febrile neutropeniaBlood and lymphatic system disorders1/2466/246
COVID-19Infections and infestations5/2466/246
JaundiceHepatobiliary disorders1/2465/246
Hepatic failureHepatobiliary disorders1/2465/246
Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2464/246
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/2464/246
FatigueGeneral disorders0/2463/246
Most frequent other events
Showing 10 of 27
Most frequent other events
EventTrifluridine/Tipiracil + BevacizumabTrifluridine/Tipiracil
NeutropeniaBlood and lymphatic system disorders153/246126/246
NauseaGastrointestinal disorders95/24669/246
AnaemiaBlood and lymphatic system disorders79/24680/246
AstheniaGeneral disorders61/24658/246
Decreased appetiteMetabolism and nutrition disorders55/24639/246
FatigueGeneral disorders54/24641/246
DiarrhoeaGastrointestinal disorders54/24647/246
VomitingGastrointestinal disorders51/24636/246
ThrombocytopeniaBlood and lymphatic system disorders44/24629/246
Neutrophil count decreasedInvestigations34/24618/246

Baseline characteristics

Full Analysis Set (FAS): all participants to whom a therapeutic unit was randomly assigned using Interactive Web Response System (IWRS). Participants were analyzed in the arm they were assigned by randomization.

Age, Continuous
Age, Continuous(years)Trifluridine/Tipiracil + BevacizumabTrifluridine/TipiracilTotal
Median62.00 (20.0 to 84.0)64.00 (24.0 to 90.0)63.00 (20.0 to 90.0)
Age, Customized
Age, Customized(Participants)Trifluridine/Tipiracil + BevacizumabTrifluridine/TipiracilTotal
Adults (18-64 years)146129275
From 65-84 years100116216
85 years and over011
Sex: Female, Male
Sex: Female, Male(Participants)Trifluridine/Tipiracil + BevacizumabTrifluridine/TipiracilTotal
Female124112236
Male122134256
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Trifluridine/Tipiracil + BevacizumabTrifluridine/TipiracilTotal
American Indian or Alaska Native101
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American437
White215220435
More than one race000
Unknown or Not Reported262248
08

Study locations

99 sites
  • Mayo Clinic Hospital
    Phoenix, Arizona 85054, United States
  • City of Hope
    Duarte, California 91010, United States
  • City of Hope - South Pasedena
    South Pasadena, California 91030, United States
  • City of Hope - Upland
    Upland, California 91786, United States
  • Mayo Clinic - FL
    Jacksonville, Florida 32224, United States
  • Mount Sinai Comprehensive Cancer Center
    Miami Beach, Florida 33140, United States
  • Comprehensive Hematology Oncology
    Saint Petersburg, Florida 33709, United States
  • DuPage Medical Group - Joliet Oncology-Hematology Associates
    Joliet, Illinois 60435, United States
  • Investigative Clinical Research of Indiana LLC
    Noblesville, Indiana 46062, United States
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists
    Omaha, Nebraska 68130, United States
  • Mayo Clinic - Rochester
    Rochester, New York 55905, United States
  • Renovatio Clinical - El Paso
    El Paso, Texas 79915, United States
  • "Medizinische Universität Graz "
    Graz, 8036, Austria
  • "Medizinische Universität Innsbruck Univ.-Klinik für Innere Medizin V"
    Innsbruck, 6020, Austria
  • "Ordensklinikum Linz Barmherzige Schwestern Interne I"
    Linz, 4010, Austria
  • "Landeskrankenhaus Feldkirch Interne E"
    Rankweil, 6830, Austria
  • "Landeskrankenhaus (SALK) Universitätsklinik für Innere Medizin III (SALK)"
    Salzburg, 5020, Austria
  • "Landesklinikum Wiener Neustadt "
    Wiener Neustadt, 2700, Austria
  • "Allgemeines Krankenhaus - Universitätskliniken Klinische Abteilung für Onkologie"
    Wien, 1090, Austria
  • "OLV Ziekenhuis Oncology"
    Aalst, 9300, Belgium
  • "Universitair Ziekenhuis Antwerpen Oncologie"
    Edegem, 2650, Belgium
  • "UZ Leuven Campus Gasthuisberg Digestieve Oncologie"
    Leuven, 3000, Belgium
  • "CHC Montlégia Oncologie"
    Liege, 4000, Belgium
  • "AZ NIKOLAAS Oncology"
    Sint Niklaas, 9100, Belgium
  • "Hospital do Câncer de Barretos - Fundação Pio XII Unidade de Pesquisa Clínica"
    Barretos, 14784-400, Brazil
  • "Hospital de Base Centro Integrado de Pesquisa"
    Sao Jose Do Rio Preto, 15090-000, Brazil
  • "ICESP - Instituto do Câncer do Estado de São Paulo Centro Integrado de Pesquisa"
    Sao Paulo, 01246-000, Brazil
  • Hospital A C Camargo Unidade de Pesquisa Clinica Rua Antonio Prudente
    Sao Paulo, 01509-900, Brazil
  • Hospital Albert Einstein Instituto de Ensino e Pesquisa Av Albert Einstein
    Sao Paulo, 05652- 900, Brazil
  • Hospital Sao Camilo Nucleo de Pesquisa Av Alcantara Machado
    São Paulo, 03102-002, Brazil
  • "Aalborg Universitetshospital, Syd Onkologisk Afdeling"
    Aalborg, 9000, Denmark
  • Rigshospitalet Dpt of Oncology
    Copenhagen, 2100, Denmark
  • "Regionshospitalet Herning, Hospitalsenheden Vest Onkologisk Afdeling"
    Herning, 7400, Denmark
  • "Odense Universitetshospital Department of Oncology"
    Odense, 5000, Denmark
  • "CHU Jean Minjoz Service d'oncologie médicale"
    Besancon, 25030, France
  • "CHU Morvan Institut de Cancérologie et d'Hématologie"
    Brest, 29200, France
  • "Centre de lutte contre le cancer Francois Baclesse UCP Digestif"
    Caen, 14076, France
  • Hôpital Saint-Antoine Service d'Oncologie Médicale
    Paris, 75012, France
  • "Hôpital Européen Georges Pompidou Oncologie Hépatogastroenterologie-oncologie digestive"
    Paris, 75015, France
  • CHU de Poitiers Pole Régional de Cancérologie
    Poitiers, 86021, France
  • Onkologische Schwerpunktpraxis Kurfuerstendamm
    Berlin, 10707, Germany
  • Charite Universitätsmedizin Medizinische Klinik m.S. Haemat., Onko., Tumorimmunologie
    Berlin, 13353, Germany
  • Lübecker Onkologische Schwerpunktpraxis im Hochschulstadttei
    Luebeck, 23562, Germany
  • Klinikum der Universität München Campus Großhadern, Medizinische Klinik und Poliklinik III
    Muenchen, 81377, Germany
  • Magyar Honvedseg Egeszsegugyi Kozpont Onkologiai Osztaly
    Budapest, 1062, Hungary
  • Szent Imre Egyetemi Oktatokorhaz Klinikai Onkologiai Osztaly
    Budapest, 1115, Hungary
  • Debreceni Egyetem Orvos es Egeszsegtudomanyi Centrum Onkologiai Intezet
    Debrecen, 4032, Hungary
  • Petz Aladar Megyei Oktato Korhaz Onkoradiologiai Osztaly
    Győr, 9024, Hungary
  • Bacs-Kiskun Megyei Korhaz Onkoradiologiai Kozpont
    Kecskemét, 6000, Hungary
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kp. Onkoterápiás Klinika
    Szeged, 6720, Hungary
  • JNSZ Megyei Hetenyi Geza Korhaz es Rendelointezet Megyei Onkologiai Centrum
    Szolnok, 5004, Hungary
  • Markusovszky Egyetemi Oktatokorhaz Onkoradiologiai Osztaly
    Szombathely, 9700, Hungary
  • Azienda Policlinico Universitaria - Presidio Monserrato Oncologia Medica Strada Statale 554 Sestu-Monserrato
    Cagliari, Italiy 9100, Italy
  • A.O.U. Seconda Universita degli Studi di Napoli U.O.C di Oncologia Medica e di Ematologia Dipartimento Medico di Internistica clinca e sperimentale " F Magrassi - A. Lanzara" Via Sergio Pansisni ,
    Napoli, 80131, Italy
  • Istituto Nazionale Tumori, I.R.C.C.S "Fondazione G Pascale" Struttura Complessa di Oncologia Medica Addominale
    Napoli, 80131, Italy
  • Istituto Oncologico Veneto IOV - IRCCS Unita Operativa Complessa Oncologia Medica 1 Via Gattamelata 64
    Padova, 35128, Italy
  • A.O.U. Pisana-Ospedale Santa Chiara U.O. di Oncologia Medica 2
    Pisa, 56126, Italy
  • Ospedale San Carlo U.O. Oncologia Medica Via Potito Petrone, Ctr Macchia Romana
    Potenza, 85100, Italy
  • Arcispedale Santa Maria Nuova Unità di Oncologia
    Reggio Emilia, 42123, Italy
  • Istituto Clinico Humanita IRCCS Dipartimento di Oncologia Medica ed Ematologia Via Manzoni,
    Rozzano (MI), 20089, Italy
  • IRCSS Casa Sollievo della Sofferenza Dipartimento Onco-Ematologia Vale Cappuccini 1
    San Giovanni Rotondo, 71013, Italy
  • Przychodnia Lekarska "KOMED"
    Konin, 62-500, Poland
  • SP ZOZ Szpital Uniwersytecki w Krakowie Oddzial Kliniczny Onkologii
    Krakow, 31-531, Poland
  • Opolskie Centrum Onkologii im. Tadeusza Koszarowskiego Oddzial Onkologii Klinicznej
    Opole, 45-061, Poland
  • Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku Sp. z o.o.
    Słupsk, 76-200, Poland
  • Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy Klinika Onkologii i Radioterapii
    Warszawa, 02-034, Poland
  • Wojskowy Instytut Medyczny Klinika Onkologii
    Warszawa, 04-141, Poland
  • Centralny Szpital Kliniczny MSWiA Oddział Radioterapii i Onkologii
    Warzszawa, 02-507, Poland
  • Pan American Center for Oncology Trials, LLC
    Río Piedras, 00935, Puerto Rico
  • Arkhangelsk Clinical Oncology Dispensary chemotherapy department
    Arkhangelsk, 163045, Russian Federation
  • Clinical Oncology Dispensary No.1 Chemotherapy Department
    Krasnodar, 350040, Russian Federation
  • Moscow City Oncology Hospital # 62 chemotherapy department
    Moscow Region, 143423, Russian Federation
  • Russian Cancer Research Center n.a. NN Blokhin Clinical Pharmacology and Chemotherapy
    Moscow, 115478, Russian Federation
  • University Headache Clinic Outpatient oncology clinic
    Moscow, 121467, Russian Federation
  • Omsk Clinical Oncologic Dispensary Chemotherapy
    Omsk, 644046, Russian Federation
  • National Medical Research Center of Oncology N.N. Petrova
    Saint-petersburg, 197758, Russian Federation
  • Multidisciplinary clinic "Reaviz
    Samara, 443011, Russian Federation
  • Oncology dispensary No.2 Oncology department
    Sochi, 354057, Russian Federation
  • Scientific Centre for Specialized Medical Care (oncological) Chemotherapy
    St Petersburg, 115478, Russian Federation
  • Saint Petersburg City Oncology Clilnic
    St Petersburg, 198255, Russian Federation
  • SBIH of YR "Clinical oncology hospital chemotherapy department"
    Yaroslavl, 150054, Russian Federation
  • "H. Valle de Hebrón Servicio de Oncología - (VHIR)"
    Barcelona, 08035, Spain
  • "Hospital de la Santa Creu I Sant Pau Oncología Medica"
    Barcelona, 08041, Spain
  • "Hospital Uni. Reina Sofía - Hospital Provincial Departamento de Oncología Médica"
    Cordoba, 14004, Spain
  • "INSTITUTO CATALAN DE ONCOLOGÍA - ICO Oncología Médica"
    Hospitalet de Llobregat, 08908, Spain
  • "Hospital Universitario Ramón y Cajal Servicio de Oncologia Médica"
    Madrid, 28034, Spain
  • "HOSPITAL 12 DE OCTUBRE Servicio Oncología Médica"
    Madrid, 28041, Spain
  • "Hospital Universitario Marqués de Valdecilla oncología medica"
    Santander, 39008, Spain
  • H.VIRGEN DEL ROCIO Servicio de Oncología Médica
    Sevilla, 41013, Spain
  • H. GENERAL DE VALENCIA Servicio de Oncología Médica
    Valencia, 46014, Spain
  • Hospital Universitario Miguel Servet Edif. de maternidad planta 8. Servicio de Oncología Médical
    Zaragoza, 50009, Spain
  • Kyiv City Clinical Oncological Centre
    Kiev, Ukrain 03115, Ukraine
  • Cherkasy Regional Oncological Dispensary Regional Clinical Oncological Centre
    Cherkassy, 18009, Ukraine
  • "MI ""Dnipropetrovsk City Multi-field Clinical Hospital #4"" Department of Oncology"
    Dnipro, 49102, Ukraine
  • LLC Ukrainian Center of Tomotherapy "Tomoclinic", Chemoteraphy Department
    Kropyvnytskyi, 25011, Ukraine
  • National Institute of Cancer Abdominal Oncology Department
    Kyiv, 03022, Ukraine
  • Medical Center n.a. Acad. Spizhenko "Syber Clinic Spizhenko"" Department of Oncology
    Kyiv, 08112, Ukraine
  • "Clinical and diagnostic Centre of Medics-rey Inter. Group LLC Hospital of Israeli Oncology "LISOD"
    Kyiv, 08720, Ukraine
  • Podillia Regional Oncology Centre Chemotherapy Department
    Vinnitsya, 21029, Ukraine
09

References and documents

Publications

  • Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Cruz FM, Wyrwicz L, Stroyakovskiy D, Papai Z, Poureau PG, Liposits G, Cremolini C, Bondarenko I, Modest DP, Benhadji KA, Amellal N, Leger C, Vidot L, Tabernero J; SUNLIGHT Investigators. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med. 2023 May 4;388(18):1657-1667. doi: 10.1056/NEJMoa2214963. PubMed 37133585 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jul 2022, 19 months.

Results were first posted in Dec 2023, 1 year 5 months after primary completion. A results delay was requested in Jul 2023.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 19 months is below that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2021
First posted
Feb 3, 2021
StartActual
Nov 25, 2020
Primary completionActual
Jul 19, 2022
CompletionActual
Sep 12, 2023
Results delay requested
Jul 12, 2023
Results first posted
Dec 26, 2023
Last update
Sep 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04737187
Collaborators
Institut de Recherches Internationales Servier
Responsible party
Sponsor
First posted
Feb 3, 2021
Start date
Nov 25, 2020
Primary completion
Jul 19, 2022
Completion
Sep 12, 2023
Results posted
Dec 26, 2023
Last update
Sep 24, 2024

Study contacts

Josep Tabernero, Prof
principal investigator · Vall d'Hebron Institute of Oncology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion